"Zota is Work in Progress", Focus Remains on Tomi - Stifel Maintains eFFECTOR Therapeutics (EFTR) at Hold
Tweet Send to a Friend
Stifel analyst Benjamin J. Burnett reiterated a Hold rating on eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), following the company's ASCO presentations ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
